SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

BABA is facing downward pressure amid reports of internal security bans regarding foreign AI coding tools and ongoing legal headwinds, leading to intense community debate between those viewing it as a distressed value opportunity and others calling it a permanent value trap. The stock remains highly volatile as traders focus on its oversold RSI levels and institutional rebalancing, with many investors debating whether its current technical weakness marks a bottom or a continued downtrend.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals is seeing significant market interest driven by rumors of a potential buyout and excitement over the company's strategic pivot to cut costs by closing internal research facilities. Investors are actively discussing the stock's high short interest and its potential as a prime acquisition target, leading to increased volume and bullish sentiment surrounding its core commercial products.

Direxion Shares ETF Trust - Direxion Daily MSCI South Korea Bull 3X ETF

Direxion Daily South Korea Bull 3X Shares

KORU is experiencing extreme volatility and intense community debate, driven by a convergence of major catalysts including upcoming SK Hynix listings and scheduled stock splits. Traders remain sharply divided between those capturing rapid gains from the fund's 3x leverage and those warning of the severe risks inherent in such aggressive, momentum-sensitive instruments.

American Bitcoin Corp. engages in the management of a bitcoin accumulation platform. It offers exposure to bitcoin through an industry-first business model that integrates scaled self-mining operations with disciplined accumulation strategies. The company was founded by Eric Trump and Donald John Trump Jr. on October 3, 2018 and is headquartered in Miami, FL.

American Bitcoin Corp. - Ordinary Shares - Class A

American Bitcoin Corp.

American Bitcoin Corp. is experiencing intense volatility and speculative fervor as investors debate its role in the broader crypto infrastructure sector and its controversial ties to the Trump family. The community remains deeply divided, with some traders citing accumulation patterns and a potential bull run in Bitcoin as catalysts, while others actively warn of a recurring cycle of reverse stock splits and share dilution.

USA Rare Earth, Inc. is a domestic supplier of rare earth magnets and heavy rare earth elements. It develops a vertically integrated domestic supply chain for rare earth element magnet production, with a facility in Stillwater and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth is experiencing extreme volatility as investors weigh the potential dilution from a new large-scale share resale filing against the company's massive government funding and strategic expansion. While community sentiment remains split between long-term confidence in its domestic supply chain dominance and frustration over recent sharp price declines, traders are actively debating whether current support levels offer a buy-the-dip opportunity or if further downside is likely.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded by Keyvan Mohajer, Majid Seyed Emami and James M. Hom on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is experiencing significant community buzz due to its high short interest and speculative potential as an 'agentic AI' leader, with retail investors actively debating whether a technical breakout is imminent. Discussion remains polarized, centered on intense short-squeeze theories, the upcoming merger timeline, and frustration over the stock's recent volatility compared to broader AI sector gains.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is seeing significant upward momentum as investors speculate on potential buyout interest and anticipate upcoming clinical data from the maintenance study of its obesity drug, VK2735. The stock is currently a major talking point in the healthcare sector, with the community actively discussing institutional accumulation, potential short-squeeze dynamics, and the broader competitive landscape for next-generation weight-loss medications.

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Boston Scientific Corp.

Boston Scientific is currently trending as investors debate whether the stock is a deep-value opportunity after a recent price slide or a falling knife in a sector being bypassed for high-momentum AI plays. The community is actively discussing aggressive insider buying and share buybacks as potential indicators that the stock is oversold, while others remain cautious due to management's recent guidance and persistent technical pressure.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. (CRML) is currently generating significant community buzz due to its role in the strategic Greenland rare-earth trade, fueled by renewed government focus on Arctic resources and the need to reduce reliance on foreign supply chains. Investors are actively debating the company's long-term potential as they await catalytic updates on the Tanbreez project's feasibility studies and drilling progress to justify its current market valuation.

Senseonics Holdings, Inc. is a medical technology company, which engages in the development and manufacture of glucose monitoring products. Its primary product is the brand Eversense CGM (continuous glucose monitoring) including sensors, smart transmitters, and mobile applications. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.

Senseonics Holdings Inc

Senseonics Holdings is facing intense community skepticism and downward pressure following the announcement of an $80 million public offering of common stock and pre-funded warrants. Investors are vocally criticizing the management team's history of dilution and the potential for further share devaluation, fueling widespread frustration over leadership performance and long-term capital strategy.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Elliott Sees Hidden Billions Inside Bio-Rad Laboratories

Elliott Management builds a stake in Bio-Rad (NYSE: BIO) to push for better performance, but family voting control could pose a hurdle.read more...

Bio-Rad to Participate in Upcoming Investor Conferences

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company will participate in the following...

Bio-Rad Laboratories (NYSE:BIO.B) Trading Down 12.8% - Time to Sell?

Bio-Rad Laboratories (NYSE:BIO.B) Trading Down 12.8% - Here's Why...

Bio-Rad Laboratories (NYSE:BIO.B) Shares Gap Down   - Should You Sell?

Bio-Rad Laboratories (NYSE:BIO.B) Shares Gap Down - Here's What Happened...

Bio-Rad Laboratories, Inc. (NYSE:BIO) Receives Average Rating of "Hold" from Analysts

Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Get Free Report) have earned an average rating of "Hold" from the five brokerages that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendat...

Unlocking Bio-Rad (BIO) International Revenues: Trends, Surprises, and Prospects

Explore how Bio-Rad's (BIO) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.

Wells Fargo & Company Has Lowered Expectations for Bio-Rad Laboratories (NYSE:BIO) Stock Price

Wells Fargo & Company decreased their target price on Bio-Rad Laboratories from $320.00 to $290.00 and set an "equal weight" rating for the company in a research note on Friday...

Bio-Rad Laboratories (NYSE:BIO) Shares Gap Down Following Weak Earnings

Bio-Rad Laboratories (NYSE:BIO) Shares Gap Down After Earnings Miss...

Bio-Rad Laboratories Q1 Earnings Call Highlights

Bio-Rad Laboratories (NYSE:BIO) reported first-quarter 2026 results that fell within its revenue guidance range, while management emphasized that geopolitical disruption in the Middle East and continued weakness in academic research demand are weighing on growth and profitability expectations for th...

Bio-Rad Laboratories (NYSE:BIO) Announces Earnings Results

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) announced its quarterly earnings data on Thursday. The medical research company reported $1.89 earnings per share for the quarter, missing analysts' consensus estimates of $1.97 by ($0.08). The business had revenue of $592.10 million during the...

Bio-Rad Laboratories, Inc. engages in the development, manufacturing, and marketing of a portfolio of instruments, systems, reagents, and consumables. It operates through the following segments: Life Science and Clinical Diagnostics. The Life Science segment includes development, manufacturing, and marketing of instruments, systems, reagents, and consumables used to separate, purify, characterize, and quantify biological materials. The Clinical Diagnostics segment focuses on designing, manufacturing, marketing, and support of diagnostic test systems, informatics solutions, test kits, and specialized quality controls for clinical laboratories in the global diagnostics market. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.

Bio-Rad Laboratories Inc. - Ordinary Shares - Class A

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	$1.75	--	--	N/A
Q1 '26	$1.97	$1.89	-4.21%	MISSED
Q4 '25	$2.71	$2.51	-7.31%	MISSED
Q3 '25	$1.95	$2.26	15.66%	BEAT
Q2 '25	$1.73	$2.61	50.52%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

BIOBio-Rad Laboratories Inc. - Ordinary Shares - Class A

Upcoming Earnings: Q2 '26

Historical Earnings

Latest BIO News